FMISO

FMISO is a radiopharmaceutical used in PET imaging. It is a hypoxia marker, meaning it is used to detect areas of low oxygen in the body. This is particularly useful in oncology, as hypoxic cells are often more resistant to radiation therapy and chemotherapy, and thus can be a sign of a more aggressive tumor.

Chemistry

FMISO, or Fluoromisonidazole, is a nitroimidazole compound. It is labeled with the radioisotope F-18, which emits positrons that can be detected by a PET scanner. The nitroimidazole moiety of FMISO is reduced in hypoxic cells, trapping the compound within the cell. This allows for the visualization of hypoxic regions within a tumor.

Clinical Use

FMISO is used in PET imaging to detect hypoxic regions within tumors. This can be useful in determining the aggressiveness of a tumor, as hypoxic cells are often more resistant to treatment. FMISO can also be used to guide treatment planning, as it can help identify areas that may require more aggressive treatment.

Research

Research is ongoing into the use of FMISO in other areas of medicine. For example, it has been suggested that FMISO could be used to detect hypoxia in cardiovascular disease, as hypoxic cells are also present in conditions such as myocardial infarction and stroke.

See Also

• Radiopharmaceutical
• Positron Emission Tomography
• Hypoxia (medical)
• Oncology
• Tumor
• Fluorine-18
• Radioisotope
• Positron
• Cardiovascular disease
• Myocardial infarction
• Stroke

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia